Different subsets of macrophages in the synovial tissue could help predict whether patients with rheumatoid arthritis will experience flares following treatment discontinuation, researchers report in Nature Medicine.
Preliminary findings from the GRECCO-19 trial suggest that colchicine, an anti-inflammatory drug used in the treatment of gout and familial Mediterranean fever, may have potential as a therapeutic agent for COVID-19.
The likelihood of experiencing an adverse event after initiating treatment with a first biologic DMARD increases with age and is higher in women than men, show data from a real-world study among people with rheumatic diseases.
Diacerein has comparable efficacy to celecoxib for pain reduction in patients with moderate-to-severe symptomatic knee osteoarthritis and is well tolerated, suggest study findings reported in Rheumatology.
Rheumatic diseases and their treatments may not be associated with outcomes of SARS-CoV-2 infection, but older age and comorbidities are likely risk factors for a severe COVID-19 disease course in rheumatology patients, suggest findings from two studies.
Both underweight and obese people with rheumatoid arthritis are at increased risk for discontinuing TNF inhibitor treatment earlier than their normal weight counterparts, real-world study findings indicate.
Preliminary findings from the Spanish BIOBADASER registry suggest that patients with rheumatic and musculoskeletal diseases may not have an elevated risk for COVID-19 hospitalization or mortality compared with the general population.